Menu
Recruiting NCT06203327

Atrophic Gastritis Predicts the Risk of Gastric Cancer

— Observational Atrophic Gastritis

For patients and families

In plain language

An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.

What is being studied
The protocol lists: Esophagogastroscopy (OLGA 0-Ⅰ), Esophagogastroscopy (OLGA II), Esophagogastroscopy (OLGA III-IV).
Who it may be relevant to
Registry conditions: Atrophic Gastritis. Basic parameters: 18 years — 70 years · All.
What needs checking
Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
Where it takes place
China
Next step
Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →

Unsure about the terms? Read our patient guide →

Official title

Atrophic Gastritis Predicts the Risk of Gastric Cancer: a Prospective Cohort Study

Overview

Despite declining incidence rates, gastric cancer (GC) ranks the fourth leading cause of cancer-related mortality and the fifth most common cancer worldwide, with the highest incidence reported in Eastern Asia. The 5-year overall survival rate of early GC exceeds 90%, which was well above advanced GC. Most intestinal-type GCs follow the Correa cascade-inflammation,atrophy, intestinal metaplasia (IM), dysplasia and subsequent carcinoma. The presence of gastric mucosal atrophy and intestinal metaplasia are important risk factors for GC. The purpose of this study was to investigate the incidence of GC attributed to atrophic gastritis in a region with high incidence of GC.

Interventions

  • Other Esophagogastroscopy (OLGA 0-Ⅰ)
    Surveillance endoscopies at years 3-5.
  • Other Esophagogastroscopy (OLGA II)
    Surveillance endoscopies at years 2-3.
  • Other Esophagogastroscopy (OLGA III-IV)
    Surveillance endoscopies every year.

Primary outcome measures

  • early gastric neoplasm [Time frame: After the baseline endoscopy, participants were scheduled for surveillance endoscopies at years 3-5 for subjects with operative link on gastritis assessment (OLGA) 0-Ⅰ, at years 2-3 for subjects with OLGA II and 1 year for subjects with OLGA III-IV.]

Eligibility criteria

Inclusion criteria

  • Ability and willingness to participate in the study and to sign and give informed consent
  • Biopsies were collected based on the recommendation of updated Sydney system

Exclusion criteria

  • under 18 or over 80 years old
  • history of gastrectomy
  • severe systemic diseases or malignancy

Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.

Healthy volunteers: No

Study design

Observational model
Cohort

Study locations

China · 1 center
  • Renji Hospital, School of Medicine, Shanghai Jiao Tong University — Shanghai

Identifiers

NCT: NCT06203327 · rjhy20230004

Primary sources (government registries)

View this study on ClinicalTrials.gov ↗